<?xml version='1.0' encoding='utf-8'?>
<document id="27098526"><sentence text="Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms."><entity charOffset="31-41" id="DDI-PubMed.27098526.s1.e0" text="Rifampicin" /></sentence><sentence text="Since many drugs are cytochrome P450 (CYP)-3A4 substrates, it has become common practice to assess drug-drug interaction (DDI) potential with a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) in early drug development"><entity charOffset="162-174" id="DDI-PubMed.27098526.s2.e0" text="ketoconazole" /><entity charOffset="188-198" id="DDI-PubMed.27098526.s2.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.27098526.s2.e0" e2="DDI-PubMed.27098526.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27098526.s2.e0" e2="DDI-PubMed.27098526.s2.e1" /></sentence><sentence text=" Such an evaluation is relevant to anticancer drugs with metabolism governed by CYP3A4" /><sentence text=" DDIs with rifampicin are complex, involving other physiological mechanisms that may impact overall pharmacokinetics"><entity charOffset="11-21" id="DDI-PubMed.27098526.s4.e0" text="rifampicin" /></sentence><sentence text=" Our objective was to study and delineate such mechanisms for oral versus intravenous anticancer drugs" /><sentence text=" We hypothesized that DDIs between anticancer drugs and rifampicin were primarily driven by CYP3A4 induction"><entity charOffset="56-66" id="DDI-PubMed.27098526.s6.e0" text="rifampicin" /></sentence><sentence text=" This hypothesis was proven for the oral anticancer drugs; however, in some cases, other intrinsic mechanisms such as P-glycoprotein (Pgp)/UDP glucuronosyl transferase (UGT) induction and transporter inhibition may have played an important role alongside the induced CYP3A4 enzymes" /><sentence text=" The hypothesis that CYP3A4 induction would decrease drug exposure appeared paradoxical for intravenous romidepsin and-to a somewhat lesser extent-for cabazitaxel"><entity charOffset="151-162" id="DDI-PubMed.27098526.s8.e0" text="cabazitaxel" /></sentence><sentence text=" In light of this dilemma in the interpretation of the pharmacokinetic data with rifampicin, several questions require further consideration"><entity charOffset="81-91" id="DDI-PubMed.27098526.s9.e0" text="rifampicin" /></sentence><sentence text=" Given the complexity and paradoxical effects arising with DDIs with rifampicin, the continued preference for rifampicin as CYP3A4 inducer needs immediate re-appraisal"><entity charOffset="69-79" id="DDI-PubMed.27098526.s10.e0" text="rifampicin" /><entity charOffset="110-120" id="DDI-PubMed.27098526.s10.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.27098526.s10.e0" e2="DDI-PubMed.27098526.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27098526.s10.e0" e2="DDI-PubMed.27098526.s10.e1" /></sentence><sentence text=" " /></document>